Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Theriva Biologics ( (TOVX) ) has shared an announcement.
Theriva Biologics announced the results of a Phase 1 study on VCN-01, an oncolytic adenovirus, in refractory retinoblastoma patients. The study, presented at the 2025 ASCO annual meeting, showed that VCN-01 was well tolerated with no significant toxicities, and demonstrated promising antitumor activity, avoiding eye enucleation in some cases.
The most recent analyst rating on (TOVX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Average Trading Volume: 910,040
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.82M
For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.